Takeaways: The approval expands Biocon’s immunology footprint in Canada by rounding out the Yesintek portfolio with an autoinjector alongside the already-approved prefilled syringe, vi...
Takeaways: Alberta’s coverage broadens Elidel’s public-access footprint in Canada and should make it easier for dermatologists to use a non-corticosteroid topical when conventional therapies are...
Takeaways: Rhapsido gives Canadian clinicians a first-in-class, oral BTK inhibitor option for CSU patients who are still symptomatic on H1 antihistamines, adding a targeted,...
Takeaways: GSK’s prefilled Shingrix syringe should improve operational convenience for clinics and pharmacies by removing the reconstitution step, which can reduce preparation time, ha...
Takeaways: Jupiter’s ALA-002 deal gives it a high-upside, FDA-designated NCE asset in the emerging U.S. psychedelic therapeutics space, expanding the company from one CNS program to two clinical...
Takeaways: Health Canada’s go‑ahead for Devonian’s seamless Phase II/III pediatric Thykamine program positions the company to enter a crowded but fast‑growing non‑steroidal topica...
Takeaways: Aspen-Semaglutide’s approval introduces the generic Ozempic-equivalent into Canada’s GLP‑1 space, setting up price competition and broader access in type 2 diabetes once API supply co...
Takeaways: Leqembi’s positive reimbursement step in Canada is a meaningful commercial win because it could unlock public coverage for the first disease-modifying Alzheimer’s therapy in the count...
Takeaways: Septa’s acquisition of CeeNU from Bristol Myers Squibb turns it into a supply‑critical oncology player in Canada, securing an essential chemotherapy that has faced...
Takeaways: Lenivia’s launch in Canada and the EU adds a three‑month, injectable biologic into Zoetis’ canine OA toolkit, which is likely to shift more chronic pain management away from dail...
